Phaarmasia Ltd
Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets
- Market Cap ₹ 21.9 Cr.
- Current Price ₹ 32.0
- High / Low ₹ 64.8 / 23.6
- Stock P/E
- Book Value ₹ 12.8
- Dividend Yield 0.00 %
- ROCE -16.5 %
- ROE -16.7 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Debtor days have improved from 80.9 to 46.6 days.
Cons
- Stock is trading at 2.50 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 4.10% over past five years.
- Company has a low return on equity of -10.7% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
15.16 | 12.30 | 13.68 | 14.33 | 18.97 | 23.97 | 19.93 | 16.20 | 16.88 | 27.42 | 30.59 | 24.37 | |
14.32 | 11.35 | 12.94 | 14.19 | 18.31 | 23.24 | 19.11 | 16.26 | 18.62 | 28.97 | 31.41 | 26.38 | |
Operating Profit | 0.84 | 0.95 | 0.74 | 0.14 | 0.66 | 0.73 | 0.82 | -0.06 | -1.74 | -1.55 | -0.82 | -2.01 |
OPM % | 5.54% | 7.72% | 5.41% | 0.98% | 3.48% | 3.05% | 4.11% | -0.37% | -10.31% | -5.65% | -2.68% | -8.25% |
0.00 | 0.07 | 0.01 | 0.58 | 0.53 | 0.60 | 0.58 | 0.89 | 0.47 | 0.52 | 0.66 | 0.75 | |
Interest | 0.02 | 0.03 | 0.01 | 0.01 | 0.04 | 0.04 | 0.04 | 0.01 | 0.00 | 0.04 | 0.04 | 0.02 |
Depreciation | 0.38 | 0.76 | 0.50 | 0.44 | 0.47 | 0.46 | 0.40 | 0.34 | 0.29 | 0.36 | 0.34 | 0.32 |
Profit before tax | 0.44 | 0.23 | 0.24 | 0.27 | 0.68 | 0.83 | 0.96 | 0.48 | -1.56 | -1.43 | -0.54 | -1.60 |
Tax % | 18.18% | 39.13% | 83.33% | 37.04% | 16.18% | 6.02% | 44.79% | 33.33% | -1.28% | -11.89% | -5.56% | -0.62% |
0.35 | 0.14 | 0.04 | 0.16 | 0.57 | 0.78 | 0.54 | 0.31 | -1.55 | -1.26 | -0.52 | -1.59 | |
EPS in Rs | 0.51 | 0.21 | 0.06 | 0.23 | 0.83 | 1.14 | 0.79 | 0.45 | -2.27 | -1.85 | -0.76 | -2.33 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 4% |
3 Years: | 13% |
TTM: | -20% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -1% |
TTM: | -206% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 11% |
1 Year: | -24% |
Return on Equity | |
---|---|
10 Years: | -2% |
5 Years: | -8% |
3 Years: | -11% |
Last Year: | -17% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 | 6.83 |
Reserves | 0.62 | 6.28 | 5.04 | 4.83 | 5.20 | 5.99 | 6.58 | 6.83 | 5.23 | 3.98 | 3.47 | 1.91 |
0.00 | 0.11 | 0.09 | 0.07 | 0.22 | 0.19 | 0.08 | 0.05 | 0.03 | 0.27 | 0.14 | 0.01 | |
5.91 | 6.17 | 6.74 | 7.81 | 9.67 | 20.25 | 20.11 | 8.20 | 9.12 | 17.34 | 21.01 | 12.81 | |
Total Liabilities | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 21.56 |
10.51 | 15.61 | 14.11 | 13.74 | 14.18 | 13.80 | 13.40 | 13.06 | 12.76 | 12.79 | 12.48 | 12.32 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
2.85 | 3.78 | 4.59 | 5.80 | 7.74 | 19.46 | 20.20 | 8.85 | 8.45 | 15.63 | 18.97 | 9.24 | |
Total Assets | 13.36 | 19.39 | 18.70 | 19.54 | 21.92 | 33.26 | 33.60 | 21.91 | 21.21 | 28.42 | 31.45 | 21.56 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.16 | 0.48 | 0.28 | -0.08 | 0.88 | 0.06 | 0.08 | 0.25 | -0.18 | 0.65 | 0.11 | 0.00 | |
-0.17 | -0.34 | -0.28 | -0.18 | -0.92 | -0.10 | 0.00 | 0.00 | 0.01 | -0.01 | 0.00 | -0.12 | |
0.00 | 0.12 | 0.16 | -0.02 | 0.08 | 0.04 | -0.11 | -0.02 | 0.00 | -0.16 | -0.16 | -0.15 | |
Net Cash Flow | -0.01 | 0.26 | 0.17 | -0.29 | 0.04 | 0.00 | -0.03 | 0.23 | -0.17 | 0.48 | -0.06 | -0.27 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47.67 | 47.78 | 77.64 | 90.68 | 72.92 | 179.07 | 225.63 | 96.21 | 68.98 | 99.97 | 96.05 | 46.58 |
Inventory Days | 13.98 | 80.49 | 11.77 | 55.86 | 43.40 | 134.51 | 124.67 | 65.84 | 111.66 | 103.36 | 126.07 | 57.39 |
Days Payable | 57.90 | 184.68 | 216.27 | 292.87 | 249.28 | 403.08 | 374.43 | 166.48 | 214.10 | 268.79 | 297.81 | 224.33 |
Cash Conversion Cycle | 3.74 | -56.42 | -126.86 | -146.33 | -132.96 | -89.49 | -24.13 | -4.43 | -33.46 | -65.47 | -75.69 | -120.35 |
Working Capital Days | -71.75 | -79.23 | -64.04 | -43.05 | -33.67 | -10.35 | 7.33 | 8.11 | -16.87 | -37.41 | -41.05 | -71.14 |
ROCE % | 6.15% | 2.52% | 1.99% | 2.36% | 6.01% | 6.65% | 7.55% | 3.60% | -12.09% | -12.00% | -4.65% | -16.47% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 Jun - Newspaper Advertisement of the Audited Financial Results for the Quarter and Year ended 31st March, 2025
-
Integrated Filing (Financials) For The Quarter And Year Ended 31St March, 2025
29 May - Audited financial results for quarter and year ended March 31, 2025, showing net loss and auditor's unmodified opinion.
-
Financial Results For The Year Ended 31St March 2025 - Regulation 33(3) (A) Of SEBI (LODR) Regulations, 2015.
28 May - Phaarmasia Ltd announces audited FY25 financial results with net loss and unmodified audit opinion.
-
Board Meeting Outcome for Outcome Of Board Meeting
28 May - Approved FY25 audited results, auditor reports, and appointed internal and secretarial auditors.
-
Board Meeting Intimation for This Is To Inform The Stakeholders That The Board Meeting To Consider, Approve And Declare The Financial Results Of M/S. Phaarmasia Limited Will Be Held On Wednesday 28Th May, 2025 Through Audio Visual Mean From Their Corporate Office.
23 May - Board meeting on May 28 to approve audited results and appoint auditors for FY 2025-26.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company provides various therapeutic dosage combinations for Ministry of Health & Family Welfare and also for exports. In FY20, company became a Sick Industrial Company under SICA and was referred to BIFR.